Last reviewed · How we verify

NCT06206785: REPAT

Resting Energy Expenditure in Palliative Cancer Patients

Recruiting now Last updated 6 June 2025
What this trial tests

trial in Cancer in 150 participants. Currently enrolling.

Timeline
5 September 2023
Primary endpoint
30 June 2026
31 December 2027

Quick facts

Lead sponsorNorwegian University of Science and Technology
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date5 September 2023
Primary completion30 June 2026
Estimated completion31 December 2027
Sites1 location across Norway

Conditions studied

Sponsor

Norwegian University of Science and Technology

Who can join

18 and older, any sex, with Cancer or Cachexia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study purpose is to measure REE by indirect calorimetry and to determine limits of agreement with confidence intervals between measured REE and predictive equations for determination of energy requirements in patients with incurable cancer. Clinical factors associated with hyper- and hypometabolism will be elucidated. Data will be obtained from patient journals in combination with measurements of REE and registration of survival. Data will be collected at one timepoint and survival will be monitored prospectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Norwegian University of Science and Technology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06206785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing